ライフサイエンスコーパス: hepatic failure

1 and one (<1%) patient in the placebo group (hepatic failure).

2 (1%) patient in the 5.4 mg/kg group (due to hepatic failure).

3 resented with acute BCS leading to fulminant hepatic failure.

4 o liver transplantation for the treatment of hepatic failure.

5 gulopathy, hyperbilirubinemia, and fulminant hepatic failure.

6 epatocytes is a seminal feature of fulminant hepatic failure.

7 nting and treating viral and toxic fulminant hepatic failure.

8 atients with acetaminophen-induced fulminant hepatic failure.

9 flammatory response, which accompanies acute hepatic failure.

10 n developed to support patients in fulminant hepatic failure.

11 n improve liver function in a mouse model of hepatic failure.

12 ients awaiting transplantation for fulminant hepatic failure.

13 Rosiglitazone may be associated with hepatic failure.

14 nt of intracranial hypertension in fulminant hepatic failure.

15 est results to rapidly progressive and fatal hepatic failure.

16 yptogenic cirrhosis and idiopathic fulminant hepatic failure.

17 treatment of organic acidemias and fulminant hepatic failure.

18 ncluding cryptogenic cirrhosis and fulminant hepatic failure.

19 efined selection, particularly for fulminant hepatic failure.

20 develop cirrhosis, portal hypertension, and hepatic failure.

21 mild elevations in liver tests to fulminant hepatic failure.

22 sfully performed in a patient with fulminant hepatic failure.

23 halopathy but appears unchanged in fulminant hepatic failure.

24 encephalopathy and brain edema in fulminant hepatic failure.

25 r the death rate from sepsis and progressive hepatic failure.

26 function of hepatic allografts and fulminant hepatic failure.

27 c laboratory derangements to fatal fulminant hepatic failure.

28 progressive hepatic fibrosis, cirrhosis and hepatic failure.

29 iated with increased mortality and fulminant hepatic failure.

30 associated with high mortality and fulminant hepatic failure.

31 fibrogenesis, cirrhosis, carcinogenesis, and hepatic failure.

32 e excluded patients with frailty or renal or hepatic failure.

33 otransplantation for patients with fulminant hepatic failure.

34 d to acute hepatitis and rarely to fulminant hepatic failure.

35 in lymph nodes rescued the mice from lethal hepatic failure.

36 isease that can be severe resulting in acute hepatic failure.

37 brain injury, ischemic stroke, and fulminant hepatic failure.

38 of normal but almost never causes fulminant hepatic failure.

39 inical strategies for the treatment of human hepatic failure.

40 s to steatosis with mitochondrial injury and hepatic failure.

41 able, minimally invasive form of therapy for hepatic failure.

42 complications and mortality associated with hepatic failure.

43 for isolated, rapidly progressive infantile hepatic failure.

44 itonitis, hepatorenal syndrome, or fulminant hepatic failure.

45 odynamic instability or significant renal or hepatic failure.

46 s leading to liver transplantation for acute hepatic failure.

47 one of the few treatable causes of fulminant hepatic failure.

48 ival in patients with fulminant/subfulminant hepatic failure.

49 r coronary bypass surgery and the other from hepatic failure.

50 ntive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patient

51 1.60 [95% CI, 1.45-1.76] for SDI), and acute hepatic failure (1.51 [95% CI, 0.92-2.46] for SVI and 1.

52 of 11) of patients with idiopathic fulminant hepatic failure, 18% (2 of 11) of patients with a histor

53 s (3%), fatigue (3%), gastric stenosis (3%), hepatic failure (3%), liver abscesses (3%), paroxysmal a

54 under 5 years of age, including 16 for acute hepatic failure, 46 for chronic liver disease, and 11 re

55 Eight (33%) patients with fulminant hepatic failure, 97 (66%) patients with chronic liver di

56 lantation if they have evidence of fulminant hepatic failure, a life-threatening systemic complicatio

57 available to salvage patients who developed hepatic failure after a prior surgical procedure.

58 previously reported as a cause for fulminant hepatic failure after liver transplantation.

59 r identifying the mechanisms responsible for hepatic failure after major surgical intervention.

60 on at concentrations commonly encountered in hepatic failure, an event preceding the suppression of i

61 cation to prevent amplification of fulminant hepatic failure and acetaminophen-induced hepatotoxicity

62 eding, as well as in patients with fulminant hepatic failure and alcoholic hepatitis.

63 inous clinical course leading to progressive hepatic failure and death if liver transplantation is no

64 ific antibodies into mice leads to fulminant hepatic failure and death.

65 of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria.

66 (1%) patients in the durvalumab group (acute hepatic failure and hepatitis), two (1%) patients in the

67 unts for 20-40% of all instances of clinical hepatic failure and is a common reason for withdrawal of

68 Patients with fulminant/subfulminant hepatic failure and primary nonfunction following liver

69 inning to acknowledge subgroups of fulminant hepatic failure and properly randomize therapy.

70 Patient 2 developed subfulminant hepatic failure and required liver transplantation.

71 ity is commonly seen at imaging in fulminant hepatic failure and usually reflects a combination of al

72 ll 4 patients developed clinical features of hepatic failure and were retransplanted.

73 ransferred to our institution with fulminant hepatic failure and worsening hepatic encephalopathy of

74 plications of acute liver failure (fulminant hepatic failure) and a major cause of death in this cond

75 diagnosed with toxic liver disease, 58 with hepatic failure, and 31 with jaundice.

76 ting in failure to thrive, hepatomegaly, and hepatic failure, and an average life expectancy of less

77 c regression, mortality predictors were: MV, hepatic failure, and cardiovascular failure for the grou

78 ation score, vasopressor use, serum albumin, hepatic failure, and coagulopathy.

79 mmune hepatitis (AIH) can lead to cirrhosis, hepatic failure, and death.

80 as acute kidney injury, respiratory failure, hepatic failure, and hemodynamic failure; multiple organ

81 ces, including the development of cirrhosis, hepatic failure, and hepatocellular carcinoma.

82 ver disease that can develop into cirrhosis, hepatic failure, and hepatocellular carcinoma.

83 entifying patients with toxic liver disease, hepatic failure, and jaundice among patients with system

84 in settings such as traumatic brain injury, hepatic failure, and migraine headache has yet to be ful

85 ere hospitalized, four developed evidence of hepatic failure, and one died.

86 ficantly higher risk of hepatoma, cirrhosis, hepatic failure, and overall hepatic disease than those

87 cryptogenic cirrhosis, idiopathic fulminant hepatic failure, and patients with other forms of advanc

88 ere was a trend for UNOS status 1, fulminant hepatic failure, and presence of LPD to be associated wi

89 s of sudden infant death syndrome, fulminant hepatic failure, and severe complications during pregnan

90 UNOS status 1, fulminant hepatic failure, and the development of Epstein-Barr vir

91 the high levels of ammonia that circulate in hepatic failure appear to be important.

92 who die from paracetamol overdose fulminant hepatic failure as accurately as King's College criteria

93 cases, as well as in patients with fulminant hepatic failure at high risk for mortality who have not

94 nderwent liver transplantation for fulminant hepatic failure at our institution during a 5-year perio

95 Extended liver resection leads to hepatic failure because of a small remnant liver volume.

96 lantation is associated with acute fulminant hepatic failure, biliary tract necrosis and leaks, or re

97 ause of morbidity and mortality in fulminant hepatic failure but has not been well documented as a co

98 olongs survival during LPS- and GalN-induced hepatic failure by temporarily protecting hepatocytes ag

99 lows: a) chronic liver failure; b) fulminant hepatic failure; c) patients immediately status post-ort

100 T for the BMT group (39% overall mortality); hepatic failure, cardiovascular failure, and persistent

101 ention to hepatic injury and monitor risk of hepatic failure caused by coronavirus disease 2019 (COVI

102 Excluding acute hepatic failure caused by drugs, the etiology of fulmina

103 reditary tyrosinemia type I (HT1) results in hepatic failure, cirrhosis, and hepatocellular carcinoma

104 use of vasopressors/inotropes, pancreatitis, hepatic failure/cirrhosis with ascites, gastrointestinal

105 igh mortality rate associated with fulminant hepatic failure combined with the limited availability o

106 ients, including one who developed fulminant hepatic failure complicated by cerebral edema, were taki

107 After 21 days of rosiglitazone therapy, hepatic failure developed.

108 combination treatment group (encephalopathy, hepatic failure, drug-induced liver injury, oesophageal

109 l endothelium and portal tracts of fulminant hepatic failure explants, whereas there were minimal cha

110 Patients diagnosed with fulminant hepatic failure face high mortality rates.

111 se outcomes of pregnancy including fulminant hepatic failure, fetal loss, premature birth, and neonat

112 of AA included non-A, non-B, non-C fulminant hepatic failure (FHF) (3 patients), graft-versus-host di

113 During human fulminant hepatic failure (FHF) circulating levels of most hemosta

114 r support system for patients with fulminant hepatic failure (FHF) continues to be unmet.

115 Patients with fulminant hepatic failure (FHF) die with brain edema, exhibiting a

116 e of an adult female who developed fulminant hepatic failure (FHF) during the second trimester of pre

117 Fulminant hepatic failure (FHF) in humans produces a bleeding diat

118 thy residual liver mass, otherwise fulminant hepatic failure (FHF) may arise.

119 Patients with fulminant hepatic failure (FHF) often die awaiting liver transplan

120 The effect of RI on patients with fulminant hepatic failure (FHF) or chronic liver disease (cirrhosi

121 cible experimental animal model of fulminant hepatic failure (FHF) resembling the clinical condition

122 ients who received transplants for fulminant hepatic failure (FHF) were stratified separately from th

123 has a high incidence of developing fulminant hepatic failure (FHF) with significant mortality.

124 tic metabolic pathways affected by fulminant hepatic failure (FHF) would help develop nutritional sup

125 nly proven effective treatment for fulminant hepatic failure (FHF), but its use is limited because of

126 OLT) is an effective treatment for fulminant hepatic failure (FHF), but postOLT mortality is higher f

127 ogic agents in non-A, non-B (NANB) fulminant hepatic failure (FHF), but the frequency of infection wi

128 roup 1 (n = 18) were patients with fulminant hepatic failure (FHF), in group 2 (n = 3) were patients

129 ic liver transplantation (OLT) for fulminant hepatic failure (FHF), some patients develop cerebral in

130 hepatic biliary atresia (EHBA) and fulminant hepatic failure (FHF).

131 logical role of TTV in cryptogenic fulminant hepatic failure (FHF).

132 r transplantation in patients with fulminant hepatic failure (FHF).

133 following liver transplantation in fulminant hepatic failure (FHF).

134 ccurs in half of all children with fulminant hepatic failure (FHF).

135 involve the liver but rarely cause fulminant hepatic failure (FHF).

136 support for comatose patients with fulminant hepatic failure for up to 5 days.

137 Patients dying of fulminant hepatic failure, for whom no alternative therapy is avai

138 A 25-year-old man presented with fulminant hepatic failure from an unusual peripheral T cell lympho

139 ib plus pembrolizumab group (n=1 each due to hepatic failure, gastrointestinal haemorrhage, myositis,

140 of liver dysfunction in a rat model of acute hepatic failure generated by d-galactosamine (GalN) inje

141 ture was markedly increased in the fulminant hepatic failure group (mean energy expenditure, 4.05 [SD

142 Hepatic failure has been treated successfully with clini

143 rbidity (symptoms, cirrhosis) and mortality (hepatic failure, HCC) are modest in frequency.

144 utual relationships, and those, if any, with hepatic failure/hepatic encephalopathy.

145 in nine (2%; acute kidney injury, dyspnoea, hepatic failure, hepatitis, neutropenia, pneumonitis, re

146 Clinical consequences include hepatic failure, hepatocellular carcinoma, diabetes, car

147 ; cirrhosis: HR: 5.378; 95% CI: 4.363-6.631; hepatic failure: HR: 3.258; 95% CI: 2.527-4.200; overall

148 ntal protocol of LPS-induced acute fulminant hepatic failure (i.p. injection of low dose of LPS in co

149 ioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby unders

150 patocyte-like cells rescued lethal fulminant hepatic failure in a nonobese diabetic severe combined i

151 HC-TN (genotype 1a), which caused fulminant hepatic failure in a patient and, subsequently, severe h

152 a known risk for hepatoxicity, and leads to hepatic failure in a small subset of patients.

153 (LPS) and D-galactosamine (GalN) results in hepatic failure in mice.

154 worsens overall liver function, exacerbating hepatic failure in NPC disease.

155 ncy in protoporphyria, and (3) understanding hepatic failure in protoporphyria.

156 ver cirrhosis, hepatocellular carcinoma, and hepatic failure in renal transplant patients with HCV in

157 ion were biliary atresia in seven, fulminant hepatic failure in six, chronic rejection in seven, and

158 limiting liver disease that causes fulminant hepatic failure in specific high-risk groups only.

159 cebo group, including two patients (1%) with hepatic failure in the placebo group.

160 ed the effect of KGF on LPS and GalN-induced hepatic failure in vivo and on TNF- and ActD-induced hep

161 d in the differential diagnosis of fulminant hepatic failure in young patients who show no evidence o

162 de 5 adverse events (hepatitis fulminant and hepatic failure) in the atezolizumab group were consider

163 al interventions that treat complications of hepatic failure, including antibiotic administration for

164 Incidence of hepatic failure increases with the hospital length of st

165 The management of patients with fulminant hepatic failure is a major clinical endeavor.

166 Hepatic failure is commonly associated with anemia, whic

167 The pathogenesis of brain edema in fulminant hepatic failure is still unresolved.

168 (K71.0, K71.1, K71.2, K71.6, K71.8, K71.9), hepatic failure (K72.0, K72.9), or jaundice (R17) betwee

169 ) is both the leading cause of cirrhosis and hepatic failure leading to liver transplantation and a c

170 as become the leading cause of cirrhosis and hepatic failure leading to OLT.

171 prevented endotoxin-induced lethal fulminant hepatic failure, leading to dramatically enhanced surviv

172 -0.945; p = .023) whereas hepatic cirrhosis, hepatic failure, leukemia, multiple myeloma, transfer fr

173 At least in theory, anemia during hepatic failure may result from accelerated clearance of

174 n plasma and brain glutamine associated with hepatic failure may, by increasing brain GABA release, p

175 orted in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n

176 isease progression, which were attributed to hepatic failure (n=1), upper gastrointestinal haemorrhag

177 Two hamster models of hepatic failure, namely functional hepatectomy (HepX), a

178 Multivariate analysis showed hepatic failure [odds ratio (OR), 11.2], renal failure (

179 surgery and to cases of coexistent renal and hepatic failure of diverse etiology.

180 was a 13-year-old boy with acute, fulminant hepatic failure of unknown etiology who underwent cadave

181 d in the differential diagnosis of fulminant hepatic failure of unknown pathogenesis.

182 ne [1%]), physical deterioration (one [1%]), hepatic failure (one [1%]), mesothelioma (one [1%]), and

183 No fulminant hepatic failure or death was observed.

184 ed into dengue encephalopathy (eg, caused by hepatic failure or metabolic disorders), encephalitis (c

185 in developing approaches to the treatment of hepatic failure or more broadly to the treatment of comp

186 Patients were without significant renal or hepatic failure or shock at entry.

187 ar disease (OR = 2.2), renal (OR = 3.2), and hepatic failure (OR = 10.8) as independent predictors of

188 However, survival in fulminant/subfulminant hepatic failure patients was significantly higher in the

189 This higher mortality is because of hepatic failure, possibly a result of excessive diminuti

190 ed with an increased risk of bleeding: acute hepatic failure, prolonged duration of nasogastric tube

191 cute renal failure resulting from cardiac or hepatic failure, prolonged surgery, and nephrotoxic effe

192 patient died in early childhood of fulminant hepatic failure, refractory epilepsy, lactic acidemia, a

193 re related to myocardial infarction, stroke, hepatic failure, renal failure or sepsis.

194 nt for dilated cardiomyopathy, the patient's hepatic failure resolved and she made a full recovery.

195 osis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease wit

196 A 28-year-old male with fulminant hepatic failure secondary to hepatitis B was referred to

197 Adjusted for age, hepatic failure, sepsis, thrombocytopenia, blood urea ni

198 Patients with fulminant hepatic failure should be stabilized and transferred to

199 Candidates with fulminant hepatic failure (Status-1A) receive the highest priority

200 Other causes of hepatic failure, such as viruses and toxins, were exclud

201 CV infection has become the leading cause of hepatic failure that requires OLT.

202 sms may account for brain edema in fulminant hepatic failure: the osmotic effects of brain glutamine,

203 . 11.0+/-4.7, P=0.01) and fewer days free of hepatic failure to day 14 (10.8+/-5.0 vs. 11.8+/-4.3, P=

204 ation may be used in patients with fulminant hepatic failure to facilitate fluid removal and circulat

205 ease ranging from acute (including fulminant hepatic failure) to chronic hepatitis, cirrhosis, and he

206 Z scores greater than -2.0 at OLT, fulminant hepatic failure, tumor, and postOLT complications causin

207 sing cholangitis, cystic fibrosis, fulminant hepatic failure, tyrosinemia, and chronic rejection.

208 Four patients with fulminant hepatic failure underwent extracorporeal liver perfusion

209 agnosis of tumor, (v) diagnosis of fulminant hepatic failure, (vi) retransplantation, (vii) graft dis

210 Acetaminophen overdose causes massive hepatic failure via mechanisms involving glutathione dep

211 Hepatic failure was confirmed in 26 out of 38 patients,

212 Ten patients with fulminant hepatic failure were excluded from the study, leaving 99

213 asogastric intubation, alcoholism, and acute hepatic failure were found to be independently correlate

214 , while the PPVs for toxic liver disease and hepatic failure were lower.

215 conditions like sepsis, cardiac surgery, and hepatic failure, where dysregulation can lead to seconda

216 h during the first months of life because of hepatic failure, whereas a chronic form leads to gradual

217 -induced rat model of irreversible and fatal hepatic failure, which also exhibits terminal changes in

218 r without infections, and cardiac, renal, or hepatic failure, which are common features of glycosylat

219 lthough rare, HSV-1 can also cause fulminant hepatic failure, which is often fatal.

220 of ECMO, and patients who developed renal or hepatic failure while on ECMO.

221 ld be considered for patients with fulminant hepatic failure who are appropriate transplant candidate

222 can aid in early detection of patients with hepatic failure who are unable to appropriately metaboli

223 ffering from acetaminophen-induced fulminant hepatic failure who were sedated, paralyzed, and mechani

224 sickle cell disease, who developed fulminant hepatic failure with subsequent extreme hyperbilirubinem

225 She progressed to haemodynamic and hepatic failure, with clinical features of acute-on-chro

226 Patients meeting criteria for fulminant hepatic failure without acetaminophen toxicity (FHF-NA,

227 hunt group 1 have died of late postoperative hepatic failure without benefit of liver transplantation